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engraftment after emergent substitution of ﬂudarabine (FLU)
for CY due to acute cardiac toxicity. Case 1 is a 6-mo-old
female with 11q23+ AML who underwent MRD BMT in CR1
with a planned preparative regimen of BU/CY. BU adminis-
trationwas completedwith targeted PKs; however, screening
creatine kinaseprior to scheduledCYadministrationonday-5
showed a markedly elevated level of 301 IU/dl with a normal
EKG. Troponin1 level was also very elevated at 0.49 ng/ml.
Fludarabine (FLU) was substituted for CY at 1.3mg/kg/dose
from day -5 through day -2. Neutrophil and platelet engraft-
ment occurred on day +11 and she remains 99% donor 3 yrs
post-BMT. Case 2 is a 3-yr-old female with primary myeloﬁ-
brosis who underwent a 10/10 MUD HSCT with a planned
preparatory regimen of CY/TBI. She received one dose of CYat
60 mg/kg but developed low voltage on her screening EKG
prior to the second dose. CKwas normal. FLUwas substituted
for the remaining dose of CY at 30 mg/m2/dose and she
received the planned 1200 cGy TBI. She had neutrophil
engraftment on day +32 and platelet engraftment on day +96.
She remained 100% donor but unfortunately died 10 months
post-BMT due to GVHD. Both patients had no further cardio-
vascular toxicity other than hypertension. CY induced hem-
orrhagic myocarditis is invariably fatal. Screening tests with
serum CK and EKG may be used to predict early signs of car-
diac toxicity. In the acute setting of cardiac toxicity, FLU offers
an appropriate therapeutic substitution to avoid further car-
diac toxicity and allow successful engraftment.275
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Introduction: Mixed chimerism (MC) and MRD strongly
predict relapse in children with ALL after allo-SCT. Pre-
emptive immunotherapy (IT), e.g. withdrawal of immuno-
suppression (WD-IS) or DLI can prevent impending relapse.
In this study we retrospectively analyzed chimerism and
MRD monitoring and the effect of pre-emptive IT.
Patients: Between January 2005 and July 2014, a total of 89
pts with ALL (pB-ALL, n¼63; T-ALL, n¼20; biphen. ALL, n¼6)
received allo-SCT in our institution. 47 pts were in CR1, 26 pts
in CR2, 15 pts were CR3 and 1 pt CR4 at time of transplant.
Donors were MSD (n¼18), MUD (n¼61) and haploidentical
(n¼10). Conditioning consisted of TBI (12 Gy) and ETO in pts
with a matched donor and FLU, THIO, MEL in haplo pts.
Methods: Chimerism was assessed weekly in peripheral
blood until day 200 and monthly thereafter. Bone marrow
analyses were done at days +30, +60, +90, +180 and +365
post-transplant. Thereby, MRD was assessed in 56 pts,
whereas no diagnostic material was available in 33 pts.
Results: 64/89 pts (72%) showed complete chimerism (CC) in
all follow-up analyses, and 25/89 pts (28%) developed MC.From 56 pts in whom MRD could be assessed, 40 pts
remained MRD negative and 16 developed MRD positivity
after transplantation. IT (WD-IS, n¼12; DLI, n¼14) was
initiated based on chimerism analysis in 22/25 pts with MC,
and was guided by MRD detection in 4 pts. For the total
cohort of pts, pEFS and pOS were 0.67 and 0.77, respectively.
Cumulative incidence (CI) of TRM and relapse (CI-R) were
0.11 and 0.24 for all pts.
Chimerism: pEFS was 0.74 in CC-pts and 0.51 in MC-pts
(p<0.032). 22/25MC-pts received pre-emptive IT resulting in
a pEFS of 0.58. Due to rapid progression IT was not initiated
in 3/25 MC pts. All MC pts without IT relapsed. While CI-TRM
remained low (0.10 for CC resp. 0.12 for MC, p>0.68) in both
groups, CI-R was 0.17 in CC- and 0.41 in MC-pts (p<0.021).
MRD: Pts were grouped according to their highest MRD
value post-transplant in MRD negative, low positive (<10E-
4), and high positive (>10E-4) pts. pEFS and pOS were 0.82
and 0.95 in MRD negative (n¼40), 0.56 and 0.88 in low level
MRD (n¼8), and 0.25 and 0.25 in high level MRD (n¼8)
positive pts (p<0.001). CI-Rwas 0.14 inMRD negative, 0.36 in
MRD low, and 0.75 inMRD high positive pts (p<0.001), while
CI-TRM between these groups remained low (0.05 for MRD
negative, 0.13 for MRD low and 0.00 for MRD high, p>0.55).
Multivariate analysis: Multivariate analysis for pEFS also
indicated that MC and high level MRD were independent
poor prognostic factors (MC, p<0.049, RR 3.16 and high level
MRD, p<0.022, RR 3.99), while remission status before
transplantation, ALL lineage, donor type, graft source, T cell
depletion or sex showed no signiﬁcant inﬂuence.
Conclusion: Our results show that analysis of chimerism and
MRD allow the prediction of impending relapse in virtually
all pts with ALL and that pre-emptive IT can improve
outcome in these pts.276
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Introduction: The optimal timing of Alemtuzumab admin-
istration during RTC regimen is not well studied. Proximal
administration may lead to more in vivo T cell depletion,
decreasing GVHD but potentially increasing graft failure (GF)
and delaying immune reconstitution. Intermediate admin-
istration may improve engraftment but could lead to higher
rates of GVHD. We compared two centers’ experiences
studying the schedule of Alemtuzumab within Busulfan/
Fludarabine RTC regimen.
Methods: Pts21 years old undergoing alloHCT formalignant
and non-malignant conditions using a Busulfan-12.8-16mg/kg
